Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases

Su, Yun-Ai; Fan, Xianqun; Pang, Yan

doi:10.1039/d3bm00505d

Cited by 7 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the anterior part of the outer casing of the eye, the cornea is under constant exposure to ultraviolet radiation, infections, air pollutants, etc ., making nanoceria an ideal long-acting antioxidant due to its autoregenerative ROS-modulating property in corneal diseases . Thus, nanoceria is expected to be an excellent antioxidative platform with drug-loading capacity in treating DED. , …”

mentioning

confidence: 99%

Nanoceria-Mediated Cyclosporin A Delivery for Dry Eye Disease Management through Modulating Immune–Epithelial Crosstalk

Cui,

Chen,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Dry eye disease (DED) affects a substantial worldwide population with increasing frequency. Current single-targeting DED management is severely hindered by the existence of an oxidative stress−inflammation vicious cycle and complicated intercellular crosstalk within the ocular microenvironment. Here, a nanozyme-based eye drop, namely nanoceria loading cyclosporin A (Cs@P/ CeO 2 ), is developed, which possesses long-term antioxidative and antiinflammatory capacities due to its regenerative antioxidative activity and sustained release of cyclosporin A (CsA). In vitro studies showed that the dual-functional Cs@P/CeO 2 not only inhibits cellular reactive oxygen species production, sequentially maintaining mitochondrial integrity, but also downregulates inflammatory processes and repolarizes macrophages. Moreover, using flow cytometric and single-cell sequencing data, the in vivo therapeutic effect of Cs@P/ CeO 2 was systemically demonstrated, which rebalances the immune−epithelial communication in the corneal microenvironment with less inflammatory macrophage polarization, restrained oxidative stress, and enhanced epithelium regeneration. Collectively, our data proved that the antioxidative and anti-inflammatory Cs@P/ CeO 2 may provide therapeutic insights into DED management.

show abstract

mentioning

confidence: 99%

Nanoceria-Mediated Cyclosporin A Delivery for Dry Eye Disease Management through Modulating Immune–Epithelial Crosstalk

Cui,

Chen,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

Lycium Barbarum Polysaccharide‐Derived Nanoparticles Protect Visual Function by Inhibiting RGC Ferroptosis and Microglial Activation in Retinal Ischemia‒Reperfusion Mice

Ni,

Hu,

Zhu

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Retinal ischemia‒reperfusion (IR) is a major contributor to vision impairment and irreversible vision loss due to retinal ganglion cell (RGC) injury or loss. Contemporary therapeutic approaches predominantly focus on the amelioration of symptoms rather than addressing the fundamental etiological factors. Oxidative stress is a notable feature and an important mediator of IR damage. Lycium barbarum polysaccharide (LBP), the main active ingredient of Lycium barbarum, has various pharmacological effects, including antioxidation, immunoregulation, and neuroprotective effects. In this study, the ROS‐consumable moiety phenylboronic acid pinacol ester (PBA) is introduced to LBP molecules, which can self‐assemble into nanoparticles in aqueous solution. This nanoparticle (termed PLBP) can reduce the cellular ROS levels and enhance the antioxidant capability of RGCs by activating the NRF2 pathway, thus protecting RGCs from ferroptosis and preserving visual function in response to IR injury. PLBP also reduces neuroinflammation by inhibiting the ability of microglia to phagocytose, migrate, secrete inflammatory cytokines, and activate the NF‐κB pathway. In conclusion, this approach can be used as an inspiration for the future development of neuroprotective drugs.

show abstract

Mucoadhesive Chitosan in Drug Delivery

Laffleur

2024

Advances in Polymer Science

View full text Add to dashboard Cite

Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases

Abstract: Numerous novel nano-based ocular drug delivery systems have been developed to overcome the limitations of conventional drug delivery systems, which have demonstrated promising results in the ocular disease models and...

Cited by 7 publications

References 81 publications

Nanoceria-Mediated Cyclosporin A Delivery for Dry Eye Disease Management through Modulating Immune–Epithelial Crosstalk

Nanoceria-Mediated Cyclosporin A Delivery for Dry Eye Disease Management through Modulating Immune–Epithelial Crosstalk

Lycium Barbarum Polysaccharide‐Derived Nanoparticles Protect Visual Function by Inhibiting RGC Ferroptosis and Microglial Activation in Retinal Ischemia‒Reperfusion Mice

Mucoadhesive Chitosan in Drug Delivery

Contact Info

Product

Resources

About